Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Novo Sees Ozempic Boom Prompting Another Sales Surge
Posted
February 5, 2025
Views
1,015
Likes
32
Comments
7
Engagement
3.84%
February 5, 2025
1,015
32
7
3.84%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
4:27Now PlayingNovo Nordisk A/S expects sales to surge again this year as the Danish drugmaker builds supply for blockbuster diabetes medicine Ozempic and obesity treatment Wegovy.
Revenue will likely grow by 16% to 24% at constant exchange rates, compared with 26% for last year.
The company predicts operating profit growth as high as 27% at constant currencies this year. Bloomberg Madison Muller reports on Bloomberg Intelligence
--------
Get more on The Bloomberg Intelligence Podcast
Follow us on X
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay
Android Auto
Visit our YouTube channels:
Bloomberg Podcasts
Bloomberg Television
Bloomberg Originals
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
